Innate Pharma
IPHA
5 hedge funds and large institutions have $296K invested in Innate Pharma in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0.11% less ownership
Funds ownership: 0.22% → 0.11% (-0.11%)
29% less funds holding
Funds holding: 7 → 5 (-2)
61% less capital invested
Capital invested by funds: $760K → $296K (-$464K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$109K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
-$103K |
| 3 |
Morgan Stanley
New York
|
-$77.7K |
| 4 |
LPL Financial
San Diego,
California
|
-$52K |
| 5 |
Millennium Management
New York
|
-$11.8K |
IPHA Hedge Fund Activity: Q2 2021 in Review
5 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2021, worth a combined $296K — down 61% from $760K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $109K sold.
- 5 institutional investors held Innate Pharma (IPHA) as of Q2 2021, down from 7 in Q1 2021.
- Funds reported $296K of Innate Pharma stock for Q2 2021, down 61% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q2 2021 and 2 closed out, a net change of -2 holders.
- The largest Innate Pharma seller in Q2 2021 was Citadel Advisors, an estimated $109K sold.
Based on aggregated 13F filings for Q2 2021.